{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:04:47Z","timestamp":1793505887168,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011421","name":"Sanofi China Investment Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgme.2026.109874","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:29:36Z","timestamp":1773361776000},"page":"109874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: A multi-center prospective study"],"prefix":"10.1016","volume":"148","author":[{"given":"Duoling","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ymgme.2026.109874_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/biom13091279","article-title":"A comprehensive update on late-onset Pompe disease","volume":"13","author":"Labella","year":"2023","journal-title":"Biomolecules"},{"issue":"13","key":"10.1016\/j.ymgme.2026.109874_bb0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): an update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109874_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.10754","article-title":"Newborn screening for 6 lysosomal storage disorders in China","volume":"7","author":"Chang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ymgme.2026.109874_bb0020","article-title":"Establishment of Cutoff values for Newborn screening of six lysosomal storage disorders by tandem mass spectrometry","volume":"10","author":"Li","year":"2022","journal-title":"Front. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109874_bb0025","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109874_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ymgme.2026.109874_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"issue":"15","key":"10.1016\/j.ymgme.2026.109874_bb0040","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"Van Der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"R1","key":"10.1016\/j.ymgme.2026.109874_bb0045","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1093\/hmg\/ddz133","article-title":"Gene therapy for glycogen storage diseases","volume":"28","author":"Kishnani","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109874_bb0050","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/cjn.2016.37","article-title":"Pompe disease: diagnosis and management. Evidence-based guidelines from a Canadian expert panel","volume":"43","author":"Tarnopolsky","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109874_bb0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109874_bb0060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40120-019-00157-4","article-title":"Long-term observation of the safety and effectiveness of enzyme replacement therapy in Japanese patients with Pompe disease: results from the post-marketing surveillance","volume":"8","author":"Nagura","year":"2019","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109874_bb0065","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa","volume":"107","author":"Van Der Ploeg","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109874_bb0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2026.109874_bb0075","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109874_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109874_bb0085","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00415-021-10526-5","article-title":"Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis","volume":"269","author":"Sarah","year":"2022","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109874_bb0090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.ymgme.2026.109874_bb0095","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1007\/s00415-020-09936-8","article-title":"Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start","volume":"267","author":"Stockton","year":"2020","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109874_bb0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JND-230175","article-title":"Post-hoc nonparametric analysis of forced vital capacity in the COMET trial demonstrates superiority of Avalglucosidase alfa vs Alglucosidase alfa","volume":"11","author":"Boentert","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"issue":"12","key":"10.1016\/j.ymgme.2026.109874_bb0105","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference","volume":"184","author":"Du Bois","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109874_bb0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13023-019-1054-0","article-title":"Characteristics of Pompe disease in China: a report from the Pompe registry","volume":"14","author":"Zhao","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109874_bb0115","first-page":"17","article-title":"Infantile-onset Pompe disease with neutropenia: treatment decisions in the face of a unique phenotype","volume":"64","author":"Riedy","year":"2023","journal-title":"JIMD Rep."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:59:37Z","timestamp":1787669977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1096719226001575"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109874","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: A multi-center prospective study","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109874"}}